Avizakimab, formerly known as BOS161721, represents a novel medicinal approach to treating inflammatory diseases . This monoclonal medication selectively targets IL18, a key signaling molecule implicated in the development of several severe illnesses. Preclinical studies have shown Avizakimab’s capacity to effectively block IL-18 action, leading… Read More

Bivatuzumab BIWA 4: A New Treatment Candidate Bivatuzumab BIWA 4 shows a groundbreaking therapeutic compound for treating various malignancies. This antibody selectively attaches a critical protein participating in tumor development and progression. Early preliminary results indicate potential for substantial effectiveness and a favora… Read More